Issue of Shares and Total Voting Rights

RNS Number : 9807U
Intuitive Investments Group plc
09 April 2021
 


9 April 2021

Intuitive Investments Group plc

Issue of Shares and Total Voting Rights

Intuitive Investments Group plc (AIM: IIG) ("IIG" or the "Company"), a closed-end investment company focussed on the life sciences sector, announces that it has issued 22,624 new ordinary shares of 1p each in the Company ("Ordinary Shares") to Julian Baines, a member of the Company's investment Advisory Panel. The new Ordinary Shares have been issued at Julian's request in lieu of his annual Advisory Panel fee for the year to 14 December 2021 of £5,000. The new Ordinary Shares have been issued at yesterday's closing mid-price of 22.1p.

 

Application has been made to the London Stock Exchange for the new Ordinary Shares to be admitted to trading on AIM and it is expected trading will commence at 8.00 a.m. on 15 April 2021 ("Admission").

 

Following Admission, the total number of Ordinary Shares in the Company in issue will be 40,441,824 with one vote per share. This figure may be used by shareholders in the Company as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the share capital of the Company under the Financial Conduct Authority's Disclosure Guidance and Transparency Rules. There are no shares held in treasury.

 

For further information, please contact:

Intuitive Investments Group plc

www.iigplc.com

David Evans, Executive Chairman

Robert Naylor, CEO

Via Walbrook PR

 

 

Strand Hanson Limited - Nominated Adviser

+44 (0) 20 7409 3494

James Harris / James Dance / James Bellman

 

 

 





Turner Pope Investments (TPI) Ltd - Broker

+44 (0) 20 3657 0050

Andrew Thacker / Zoe Alexander

 

 

 

Walbrook PR Limited - Media & Investor Relations

+44 (0)20 7933 8780 or intuitive@walbrookpr.com

Sam Allen / Paul McManus

+44 (0)7502 558 258 / +44 (0) 7980 541 893

 

 

About Intuitive Investments Group plc

The Company is a newly established investing company, seeking to provide investors with exposure to a portfolio concentrating on fast growing and/or high potential Life Sciences businesses operating predominantly in the UK, continental Europe and the US, utilising the Board's experience and in particular that of the Chairman, David Evans, to seek to generate capital growth over the long term for shareholders.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
IOEEANLNESNFEEA
UK 100

Latest directors dealings